Business Context and Reporting Period
This Form 8-K is a current report filed by Cortexyme, Inc. (not Quince Therapeutics, Inc.) on March 17, 2020. The filing announces the company's financial results for the fourth quarter and full fiscal year ended December 31, 2019. The registrant is an emerging growth company incorporated in Delaware with its principal executive offices in South San Francisco, California.
Key Financial Metrics
The provided text serves as a cover document referencing a press release (Exhibit 99.1) for detailed data. Consequently, specific numerical values for revenue, profit, cash flow, margins, debt, and liquidity are not present in this filing text. The filing confirms the announcement of results but does not disclose the figures directly.
Material Changes
The filing text does not provide specific comparative data or material changes versus the prior period. It only indicates that results for the fourth quarter and full year 2019 were announced.
Guidance, Outlook, and Risks
The filing references a press release titled "Cortexyme Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update." While the title suggests the inclusion of a business update, the specific guidance, outlook, management commentary, risks, or contingencies are not detailed in this 8-K text. The information is furnished as an exhibit and is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the correct registrant name is Cortexyme, Inc. (CRTX), not Quince Therapeutics, Inc.
- Review Exhibit 99.1 (the press release) to obtain actual financial figures for Q4 and FY 2019.
- Confirm the company's status as an emerging growth company and its election regarding extended transition periods for accounting standards.
- Note that the financial information in this filing is furnished, not filed, limiting its incorporation by reference in other filings.